date,title,source
Oct-22-18,Alpine Immune Sciences Lead Program ALPN-101 Demonstrates Preclinical Activity in Inflammatory Arthritis and Neurological Inflammation,Business Wire
Nov-01-18,Alpine Immune Sciences Announces Scientific Presentations at 60th American Society of Hematology Annual Meeting and Exposition,Business Wire
Nov-05-18,Analysts Estimate Alpine Immune Sciences (ALPN) to Report a Decline in Earnings: What to Look Out for,Zacks
Nov-05-18,Alpine Immune Sciences to Present at Two Upcoming Investor Conferences,Business Wire
Nov-08-18,Alpine Immune Sciences Provides Corporate Update and Reports Third Quarter 2018 Financial Results,Business Wire
Nov-09-18,Alpine Immune Sciences Advances Oncology Programs with New ALPN-202 Preclinical Data and Key Additions to Scientific Advisory Board,Business Wire
Nov-29-18,Alpine Immune Sciences Announces ALPN-101 Data to be Included in Oral Presentation at 60th American Society of Hematology Annual Meeting and Exposition,Business Wire
Dec-03-18,Alpine Immune Sciences Showcases Key Preclinical Data at 60th American Society of Hematology Annual Meeting and Exposition,Business Wire
Jan-04-19,Angion Completes Equity Financing and Appoints Senior Executives,GlobeNewswire
Jan-16-19,Alpine Immune Sciences Announces $25 Million Private Placement,Business Wire
Jan-22-19,Alpine Immune Sciences Inc (ALPN) Executive Chairman and CEO Mitchell Gold Bought $1 million of ...,GuruFocus.com
Feb-11-19,Alpine Immune Sciences Announces First Subjects Dosed in Phase I Clinical Trial for Lead Autoimmune/Inflammatory Disease Program ALPN-101,Business Wire
Feb-19-19,Alpine Immune Sciences Presents Preclinical ALPN-101 GvHD Data at the 2019 Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR (TCT Meetings),Business Wire
Feb-27-19,Alpine Immune Sciences to Present at Two Upcoming Investor Conferences,Business Wire
